Capstone Therapeutics (NASDAQ:CAPS) Releases Quarterly Earnings Results

Capstone Therapeutics (NASDAQ:CAPS) posted its quarterly earnings data on Wednesday. The company reported ($2.67) EPS for the quarter, FiscalAI reports. Capstone Therapeutics had a negative net margin of 12.40% and a negative return on equity of 29.50%. The firm had revenue of $12.48 million for the quarter.

Capstone Therapeutics Trading Down 9.3%

Shares of CAPS stock opened at $0.53 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The company has a market cap of $4.86 million, a price-to-earnings ratio of -0.56 and a beta of -1.27. Capstone Therapeutics has a 1 year low of $0.48 and a 1 year high of $3.29. The firm has a fifty day moving average price of $0.62 and a 200-day moving average price of $0.79.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Capstone Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.55% of the company’s stock.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.